Shots:
- Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible for development, regulatory, and commercial milestones along with royalties on net sales of any approved products
- Exelixis will own all Ab sequences discovered from the collaboration for uses in oncology or other disease areas & also get an option to obtain development and commercialization rights of Invenra’s internal pipeline programs in exchange for an opt-in fee
- Under the terms of the original agreement (announced on May 02, 2018), the companies are collaborating to discover and develop mono-specific and multi-specific Abs to treat cancer by using Invenra’s Abs and B-Body platforms
Click here to read full press release/ article | Ref: Exilixis | Image: Exilixis
The post Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology first appeared on PharmaShots.